Glycaemic control in people with diabetes starting treatment with fast-acting insulin aspart : a US database study

Introduction This study investigated glycaemic control in individuals with type 1 (T1D) or type 2 diabetes (T2D) 6 months after initiating fast-acting insulin aspart (faster aspart) in a real-world setting. Methods This was a single-arm, observational study using extracted patient data from the IBM® Explorys® database (USA) for individuals with T1D or T2D initiating faster aspart (at least one prescription of faster aspart) in the study period 1 January 2018 to 27 October 2020. Clinical characteristics, including age, body mass index, and baseline HbA1c, were extracted, as well as recorded events of hypoglycaemia. The primary endpoint was the change in HbA1c from baseline to 6 months. Results A total of 787 individuals were included; 36.6% of these individuals had T1D and 63.4% had T2D (of whom 46.9% were new users of rapid-acting insulin when initiating faster aspart [T2D new users] and 53.1% were switching from another rapid-acting insulin to faster aspart [T2D switchers]). For individuals with T1D, T2D new users, or T2D switchers, estimated mean change in HbA1c from baseline to 6 months was − 0.20% (95% CI − 0.53, 0.14; p = 0.252), − 1.00% (95% CI − 1.34, − 0.67; p 8.5% subgroup, there was a significant estimated decrease in HbA1c from baseline to 6 months in individuals with T1D (− 1.2% [95% CI − 1.80, − 0.60]; p = 0.0001) or T2D (− 0.6% [95% CI − 0.92, − 0.35]; p 8.5% had significant HbA1c reductions regardless of diabetes type. Supplementary Information The online version contains supplementary material available at 10.1007/s13300-021-01165-0.